RDV (GS-5734) was obtained from Selleck Chemicals LLC (Houston, TX). The SARS-CoV-2 entry inhibitors were obtained from MolPort (Riga, Latvia). Calu-3 (ATCC HTB-55), Vero E6 (CRL-1586), and Vero-STAT1 knockout cells (CCL-81-VHG) were obtained from ATCC. Vero E6 and Vero-STAT1 knockout cells were cultured in DMEM containing 10% fetal bovine serum (FBS), 2 mM l -glutamine, 100 units/ml penicillin, 100 units/ml streptomycin, and 10 mM HEPES (pH 7.4). Calu-3 cells were cultured in Eagle's Minimum Essential Medium (ATCC 30–2003) containing 10% FBS. UNCN1T cells (a human bronchial epithelial cell line; Kerafast catalog number ENC011) were cultured in BEGM media (Bronchial Epithelial Cell Growth Medium; Lonza catalog number CC-3170) in FNC (Athena Enzyme Systems catalog number 0407) coated 96-well plates. All other reagents (molecular biology grad fine chemicals) used in the study were purchased from Sigma-Aldrich (St. Louis, MO) unless otherwise mentioned.
Calu 3 atcc htb 55
Manufactured by American Type Culture Collection
Sourced in United States
Calu-3 (ATCC HTB-55) is a human cell line derived from the lungs of a 25-year-old male with adenocarcinoma. The cells exhibit an epithelial-like morphology and are commonly used for in vitro studies.
Automatically generated - may contain errors
2 protocols using calu 3 atcc htb 55
1
SARS-CoV-2 Entry Inhibitor Evaluation
2
Cisplatin-Resistant NSCLC Cell Generation
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
Cell culture and induction of cisplatin-resistant NSCLC (CR-NSCLC) cells
The parental CS-NSCLC cell lines, including A549 (ATCC® CCL-185™), H1299 (ATCC® CRL-5803™) and Calu-3 (ATCC® HTB-55™), were purchased from American Type Culture Collection (ATCC, USA) in Jan. 2019, and cultured in the incubator with standard culture conditions (37 ℃ and 5 % CO 2 humidi ed atmosphere). The cells were authenticated by STR pro ling and were identi ed as mycoplasma-free by a commercial third-party company (Abace Biotechnology, Beijing, China). The Roswell Park Memorial Institute 1640 medium (RPMI-1640, HyClone, USA) containing 10% fetal bovine serum (FBS, Gibco, USA) was used for cell cultivation. According to the experimental procedures provided by the previous work [36, 37] and our preliminary experiments (data not shown), the CS-NSCLC cells were exposed to continuous low-dose cisplatin treatment, ranged from 0.5 μg/ml to 5 μg/ml, for 80 days in a step-wise manner to generate descendent CR-NSCLC cells (A549/DDP, H1299/DDP and Calu-3/DDP). After that, the CR-NSCLC cells were stimulated with high-dose cisplatin (25 μg/ml) for 0 h, 24 h, 48 h and 72 h, to validate the successful induction of CR-NSCLC cells.
The parental CS-NSCLC cell lines, including A549 (ATCC® CCL-185™), H1299 (ATCC® CRL-5803™) and Calu-3 (ATCC® HTB-55™), were purchased from American Type Culture Collection (ATCC, USA) in Jan. 2019, and cultured in the incubator with standard culture conditions (37 ℃ and 5 % CO 2 humidi ed atmosphere). The cells were authenticated by STR pro ling and were identi ed as mycoplasma-free by a commercial third-party company (Abace Biotechnology, Beijing, China). The Roswell Park Memorial Institute 1640 medium (RPMI-1640, HyClone, USA) containing 10% fetal bovine serum (FBS, Gibco, USA) was used for cell cultivation. According to the experimental procedures provided by the previous work [36, 37] and our preliminary experiments (data not shown), the CS-NSCLC cells were exposed to continuous low-dose cisplatin treatment, ranged from 0.5 μg/ml to 5 μg/ml, for 80 days in a step-wise manner to generate descendent CR-NSCLC cells (A549/DDP, H1299/DDP and Calu-3/DDP). After that, the CR-NSCLC cells were stimulated with high-dose cisplatin (25 μg/ml) for 0 h, 24 h, 48 h and 72 h, to validate the successful induction of CR-NSCLC cells.
About PubCompare
Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.
We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.
However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.
Ready to get started?
Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required
Revolutionizing how scientists
search and build protocols!